QIAGEN to Acquire Bioanalytical Assets from SuNyx GmbH
Advertisement
QIAGEN N.V. announced that it has entered into a definitive agreement to acquire the assets related to the bioanalytical business of SuNyx GmbH. SuNyx has developed and recently initiated marketing of its proprietary MPep and MProtChip® platforms for sample preparation of peptide and protein samples for analysis on liquid chromatography (LC)-MALDI (Matrix-Assisted Laser Desorption/Ionization) mass spectrometry (MS). These products allow examining new dimensions in sample preparation by leveraging unique, nanotechnology-based surface structures.
The combination of the acquisition of the bioanalytical business of SuNyx GmbH with the acquisition of key assets of LCI creates a complete, proprietary and technology-leading portfolio for QIAGEN in the rapidly growing market segment of sample preparation of proteins and peptides for analysis using MALDI Mass Spectrometry.
The acquisition of the bioanalytical business of SuNyX expands on a previous licensing arrangement. Subject to the terms of the acquisition agreement, QIAGEN will pay approximately US$0.8 million in cash in exchange for the relevant assets. An additional consideration of approximately US$0.8 million is subject to certain milestones. QIAGEN anticipates that the transaction will add approximately US$1 million in net sales and will have a slightly dilutive impact of approximately US$0.5 million on QIAGEN's net income in 2006 and will be accretive thereafter.